Multicenter, phase II clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer.

Oncol Lett · 2018 · PMC5835896 · PMID 29541190

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

The 3-year RFS in HLA-A*2402 matched and unmatched stage IIIb CRC groups was 46.1 and 0%, respectively (HR=0.293, 95% CI: 0.070–1.45, P=0.0789), with the HLA-A*2402 matched stage IIIb group showing a nonsignificant trend toward better survival ( Fig. 4 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.